PMID: 9555611Apr 29, 1998Paper

The cognitive efficacy of atypical antipsychotics in schizophrenia

Journal of Clinical Psychopharmacology
T Sharma, D Mockler

Abstract

Cognitive dysfunction, a symptom of schizophrenia, has been recently identified as an important measure of outcome in the treatment of this disorder. Drug-mediated symptom improvement, the traditional measure of treatment success for schizophrenia, typically fails to associate with modifications of cognitive dysfunction, resulting in a failure of the patient to reintegrate into society. A paradigm shift is now required in the conceptualization of treatment success away from symptom decrement and towards treatments that improve cognitive function. Clozapine treatment has been shown to provide a significantly greater improvement in several domains of cognitive function, especially attention and verbal fluency, compared with conventional neuroleptics, whereas risperidone appears to have a beneficial effect on working memory. These results may be because of the normalization of dopamine function by clozapine and antagonism of 5HT2 receptors.

Citations

Mar 28, 2008·Neurotoxicity Research·Márcio R MartinsJoão Quevedo
Aug 4, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·Emilio L StreckJoão Quevedo
Dec 31, 2002·Psychoneuroendocrinology·S Kasper, E Resinger
Aug 24, 2001·Schizophrenia Research·J C DreherY Burnod
Dec 12, 2001·Schizophrenia Research·Dawn I VelliganAlexander L Miller
Nov 5, 2002·Schizophrenia Research·Tomiki SumiyoshiHerbert Y Meltzer
May 27, 2003·Schizophrenia Research·William S StoneAlan I Green
Feb 15, 2001·European Psychiatry : the Journal of the Association of European Psychiatrists·F SaloméM Fayol
Oct 6, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·T Sharma
Nov 11, 1999·Proceedings of the National Academy of Sciences of the United States of America·G D HoneyT Sharma
May 17, 2007·Schizophrenia Bulletin·William S Stone, Larry J Seidman
Aug 27, 2009·Schizophrenia Bulletin·Olalla RoblesCelso Arango
Oct 6, 2000·General Hospital Psychiatry·M A Adler Cohen, J M Jacobson
Jan 29, 2010·Neuroscience and Biobehavioral Reviews·Jennifer H BarnettAndrew D Blackwell
May 10, 2000·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·I Reznik, D Paleacu
May 4, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shin-Min LeeMao-Hsiung Yen
Aug 13, 2003·Journal of Neurochemistry·M M KhanS P Mahadik
Apr 7, 2005·Brain Research Bulletin·Y LevkovitzS Fennig
Feb 8, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Emmanuel StipLuc Jean Boulay
Nov 9, 2004·Neuroscience Letters·Adalisa ReinkeJoão Quevedo
Oct 12, 2004·Schizophrenia Research·Dawn I VelliganM Lynn Crismon
Jul 18, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yue HouTao Guo
Dec 17, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Edward D Levin, N Channelle Christopher
Oct 18, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Antonio Ortega-AlvaroJuan A Micó

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here